Alectinib and brigatinib are the newest second-generation ALK inhibitors that show efficacy in patients with ALK-positive NSCLC whose disease has progressed on the first-generation ALK inhibitor crizotinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.